Company Overview and News

Monsanto rival Kaveri Seed seeks bigger pie of Indian seed market

2018-06-12 livemint
Mumbai: Kaveri Seed Co., which competes with Monsanto Co. to sell hybrid seeds in India, is seeking a bigger share of the food crop market to reduce dependence on cotton seed, its breadwinner. The company gets about 60% of revenue from cotton seed sales and the remainder from vegetable seeds and grains including paddy and corn. It aims to reverse the proportion in three years, enticed by profit margins that are almost double that of the cotton segment, executive director C.
KSCL MON 532899

Kaveri Seed: Eyes on results, buyback

2018-05-23 thehindubusinessline
The board of Kaveri Seed Company will meet on Thursday to consider the audited financial results for the quarter/year ended March 31, 2018. The board will also consider a proposal for buyback of the equity shares of the company. If the proposal is approved by the board, shareholders would be keen to know the price, issue size and mode of buyback (whether open market purchase or through tender route).
KSCL 532899 SBAZ

Ashoka Pte sells 6.60 lakh shares of Kaveri Seed Company

2018-05-19 moneycontrol
On May 18, 2018 Ashoka PTE sold 6,60,815 shares of Kaveri Seed Company at Rs 500.13 on the NSE.
KSCL 532899

BNP Paribas Arbitrage buys 4.15 lakh shares of Kaveri Seed Company

2018-03-29 moneycontrol
On March 28, 2018 BNP Paribas Arbitrage bought 4,15,000 shares of Kaveri Seed Company at Rs 485.50 on the BSE.
KSCL 532899

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...